Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 5/20 | 0.38 |
| ▸ | GCK | P35557 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 5/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 6/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4697797 | 0.90 | GCK (0.41) | MCHR1GCKTP53PPARAPPARD | |
| SCHEMBL3576199 | 0.85 | PPARG (0.40) | MCHR1PPARAPPARDPPARGDGAT1 | |
| SCHEMBL3017912 | 0.83 | PPARA (0.37) | MCHR1PPARAPPARDPPARGDGAT1 | |
| SCHEMBL3573981 | 0.81 | PPARG (0.41) | PPARAPPARDPPARGDGAT1ADORA2A | |
| SCHEMBL4700751 | 0.77 | GCK (0.41) | MCHR1GCKPPARAPPARDPPARG | |
| SCHEMBL3569793 | 0.77 | GCK (0.40) | MCHR1GCKPPARAPPARDPPARG | |
| SCHEMBL4697761 | 0.76 | DGAT1 (0.36) | MCHR1GCKPPARAPPARDPPARG | |
| SCHEMBL4922011 | 0.76 | PPARG (0.42) | TP53PPARAPPARGKCNH2 | |
| SCHEMBL3577031 | 0.76 | DGAT1 (0.43) | MCHR1PPARGDGAT1ADORA2AKCNH2 | |
| SCHEMBL334044 | 0.74 | PPARG (0.43) | PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778633-B1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-20080188473-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188473-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, PTGS1, PTGER1 | MCHR1 160/4885GCK 2750/4885TP53 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.